🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you Iannis Aifantis for the opportunity and congratulations to you and Ross Levine for your success with this incredible meeting. 🙏🏻🙏🏻 #myeloidmalignancies25 Looking forward to the next

Public Service Announcement 📢 There is no such thing as stage 5 or stage 9 cancer!🤦🏻‍♀️ Stage 4 is bad as it gets!! *Cancer grade (Gleason for prostate): what #pathologist sees 🔬 * cancer stage: extent of involvement (distant metastasis= stage 4) #BidenCancer

Our new publication is out today in the OnlineFirst section of Blood Cancer Discovery! We explored correlations between monocytic AML, genetics, and survival by leveraging a large international clinical cohort of patients with AML treated with HMA+VEN. aacrjournals.org/bloodcancerdis…

Online Now! Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia dlvr.it/TKwjF7 #stemcells

Excited to share with all our latest work on the use of single cell tools in following IDH mutant AML patients during their treatment! Out today Cell Stem Cell !! An amazing collaboration with AK Eisfeld & Elli Papaemmanuil, PhD & Dan Landau !!! Driven by the impressive Maria Sirenko

Here are a couple of conclusions from this work: a) We have defined phenotypic consequences of acquired mutations in IDH1/2AML in primary patient samples on therapy (monotherapy, + (7+3)) b) IDH1/2AML upregulates inflammation and downregulates cell proliferation and DNA damage

Congratulations to this powerhouse of a team!!! leukemia science at its best!!! #hemepath #AMLsm aficionados please dig in and enjoy!! Link to full PDF: sciencedirect.com/science/articl…

Delighted to share our study out in Cell Stem Cell today from the dream team Elli Papaemmanuil, PhD Iannis Aifantis AK Eisfeld Dan Landau! We profiled IDH-mutated AML patients to define how IDH and co-mutations shape the disease at baseline and responses to IDH-inhibitors. 🧵👇

Seemingly “easy”, but very difficult to treat AML. Amazing team work is shedding new light by breaking down hierarchies and clonal structures Maria Sirenko Iannis Aifantis Ohio State Hematology Sanam Loghavi, MD صنم لغوی 🔬🧬 Elli Papaemmanuil, PhD Dan Landau

👉👉👉Just out in AmericanJournalofHematology - our group’s new paper led by .Tapan Kadia & Hagop Kantarjian,MD || Ph2 study Results CPX-351+VEN for patients w/ R/R AML (n=33;44%2nd Salvage Tx or later;30%prior SCT:: ORR=46% w/CRc 39%) #leusm #endcancer | onlinelibrary.wiley.com/doi/10.1002/aj… | Sanam Loghavi, MD صنم لغوی 🔬🧬

In this expert panel discussion from #HOPLive, leaders in #CLL treatment explore the evolving landscape of frontline therapy, with a focus on the debate between continuous BTK inhibitor therapy and fixed-duration regimens. Mohamed Kharfan-Dabaja, MD, MBA Sanam Loghavi, MD صنم لغوی 🔬🧬 ➡️ buff.ly/NbZvqxe

Iranian filmmaker Jafar Panahi wins best film at Cannes – DW – 05/24/2025 dw.com/en/dissident-i…

Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study brnw.ch/21wSZYy

GEN-PHEN-VEN: GENetic and PHENotypic features predict VEN therapy outcomes. Like light travelling through a crystal augurs fate patterns, this paper travelling through multimodal patient data identifies patterns of patient outcomes in genetic-phenotypic space.

👉👉👉Just in time for #ASCO25 Delighted to share our brand new paper just out in L&L 📣 led by Dr .Roberta Azevedo Dr Roberta Santos Azevedo MD Anderson Cancer Center #RAS #RALD #RosaiDorfman Rashmi Kanagal-Shamanna, MD Sanam Loghavi, MD صنم لغوی 🔬🧬 Hannah Goulart iman aboudalle Gautam Borthakur tandfonline.com/doi/full/10.10…

#ASCO25 👉 #CD123 expression and its correlation with mutation profile in acute myeloid leukemia. | ⁦ASCO⁩ ⁦Roberta Azevedo⁩ & ⁦Sanam Loghavi, MD صنم لغوی 🔬🧬⁩ | ⁦Naval Daver, M.D.⁩ ⁦Naveen Pemmaraju, MD⁩ #leusm #endcancer ascopubs.org/doi/10.1200/JC…